Kidney Transplant Medicine Market to Surge from USD 12.84 Bn in 2025 to USD 19.09 Bn by 2032, Driven by a 5.82% CAGR - Coherent Market Insights

According to a recent report by Coherent Market Insights, the global Kidney Transplant Medicine Market is estimated to be valued at USD 12.84 Bn in 2025 and is expected to reach USD 19.09 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.82% from 2025 to 2032. The kidney transplant medicine market is projected to experience steady growth, driven by the increasing prevalence of kidney failure and a rising number of kidney transplant procedures globally. The growing incidence of end-stage renal disease (ESRD) has notably elevated the demand for kidney replacement therapies, such as dialysis and transplantation.

Request for Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/7872

Global Kidney Transplant Medicine Market Key Takeaways

According to Coherent Market Insights (CMI), the global kidney transplant market size is expected to grow from USD 12.84 Bn in 2025 to USD 19.09 Bn by 2032.

Global demand for kidney transplant medicines will likely surge at a CAGR of 5.82% throughout the assessment period.

Based on product type, immunosuppressants segment is set to dominate the industry, totalling a revenue of about USD 4.57 Bn in 2025.

By indication, kidney transplant rejection segment is projected to account for more than half of the global kidney transplant medicine market share in 2025.

Regarding route of administration, oral segment is anticipated to account for a market share of over 1/2 in 2025.

North America is expected to dominate the global kidney transplant medicine industry, holding a revenue share of over two-fifths in 2025. This is attributable to increasing organ transplant surgeries and continuous new product launches and approvals.

As per Coherent Market Insights’ latest kidney transplant medicine market analysis, Asia Pacific, spearheaded by India and China, will likely experience fastest growth. The region is anticipated to account for nearly 1/3 of the global market share in 2025.

Purchase Now Up to 25% Discount on This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/7872

Rising Chronic Kidney Disease (CKD) Burden Propelling Growth

Coherent Market Insights’ latest kidney transplant medicine market research report outlines significant factors driving industry growth. This includes increasing incidence of chronic kidney disease (CKD) and its progression to ESRD.

According to a report published in The Lancet, chronic kidney disease affects about 9.1% to 13.4% of the global population. This increasing CKD prevalence is expected to boost growth of the kidney transplant medicine market.

CKD often progresses to end-stage renal disease (ESRD), a condition where kidney function is severely impaired. Patients with ESRD often require dialysis or kidney transplantation to survive. The increasing number of CKD and ESRD cases has consequently increased demand for kidney transplants and associated pharmaceutical therapies.

Kidney transplant medicines are widely used for preventing organ transplant rejection and managing other health issues during kidney transplants. As the number of kidney transplants rises, especially due to ESRD, the demand for kidney transplant medicines is expected to grow significantly during the forecast period.

Also Read: Impact of Rising CKD Prevalence on Kidney Transplant Market Size & Growth (2025-2032)

Side Effects and Availability of Alternative Therapies Limiting Market Growth

The future kidney transplant medicine market outlook looks optimistic. However, factors like adverse side effects of immunosuppressive drugs and availability of alternative treatments are expected to limit market growth to some extent.

Prolonged use of kidney transplant medicines can cause serious side effects, including infection, nephrotoxicity, cardiovascular issues, malignancies, and neurotoxicity. These adverse side effects often lead to treatment discontinuation, thereby limiting overall kidney transplant medicine market demand.

A bright-looking future of kidney transplant alternatives is also expected to negatively impact the target industry. Advanced treatments like regenerative medicine and artificial kidneys could reduce dependence on transplantation. Although these medical technologies are still in their infancy, their future success may limit the kidney transplant medicine market growth.

Surge in Kidney Transplants Globally Creating Growth Avenues for Players

The number of kidney transplants performed globally is increasing substantially. This is mainly due to rising incidence of end-stage renal disease (ESRD), advancements in transplant procedures, improved access to healthcare, and supportive government policies.

According to the Global Observatory on Donation and Transplant (GODT), over 95,479 kidney transplants are carried out in the world each year. This rapid rise in kidney transplants is expected to create a plethora of opportunities for kidney transplant medicine manufacturers.

Impact of AI on the Kidney Transplant Medicine Market

Artificial Intelligence (AI) is opening new frontiers in the kidney transplant medicine industry. It is helping companies enhance diagnostic accuracy, optimize donor-recipient matching, and improve post-transplant care.

AI-powered predictive analytics enable early detection of transplant rejection and complications, supporting timely medical interventions. ML algorithms streamline organ allocation processes and personalize immunosuppressive therapies, boosting transplant success rates and patient outcomes.

AI tools also assist in the development of personalized immunosuppressive therapies. These innovations are not only improving clinical outcomes but also reshaping the competitive landscape of the kidney transplant medicine market.

Emerging Kidney Transplant Medicine Market Trends

There is a growing trend of developing newer and more effective immunosuppressive drugs with fewer side effects to improve transplant outcomes and patient survival rates. Development of such advanced therapies is expected to boost the kidney transplant medicine market growth.

Growing popularity of personalized medicine is providing a strong impetus for the expansion of kidney transplant medicine market. Top players are striving to offer personalized immunosuppressive therapies tailored to individual patient needs.

Biologics with better safety profiles are gaining traction as alternatives to conventional immunosuppressants. Rising adoption of these biologics will boost kidney transplant medicine market value during the forecast period.

Increasing support from governments and healthcare organizations to reduce the burden of kidney diseases is positively impacting kidney transplant medicine sales. For instance, the Kidney Innovation Accelerator (KidneyX), a public-private partnership between the HHS and ASN, aims to drive innovation in kidney care, including transplant technologies. Such initiatives are expected to enhance research, improve treatment outcomes, and foster growth in the kidney transplant segment.

Also Read: Kidney Dialysis Equipment Market Size, Share, & Trend Analysis Report (2025-2032)

Analyst’s View

“The global kidney transplant medicine industry is poised to grow steadily, owing to rising prevalence of CKD, increasing number of organ transplant procedures performed globally, and favorable government support,” said senior analyst Ghanshyam Shrivastava.

Current Events and Their Impact on the Kidney Transplant Medicine Market

Event	Description and Impact
Biologic License Application Submission for Imlifidase (IdeS) Expected in 2025	Description: Hansa Biopharma plans to submit a Biologics License Application (BLA) to the U.S. FDA in the second half of 2025 for imlifidase (IdeS), a promising therapy for highly sensitized kidney transplant patients, under the accelerated approval pathway. Impact: If approved, imlifidase would address a significant unmet need in desensitization therapy, expanding the market for kidney transplant medicines.
Launch of CRISPR-Cas9 Edited Organs	Description: In February 2025, eGenesis successfully transplanted a genetically engineered porcine kidney into a second patient living with end-stage kidney disease. Impact: If successful, xenotransplantation will transform organ supply, raising transplant rates and demand for immunosuppressants.
Shortage of Tacrolimus and Mycophenolate Mofetil in North America (2024-2025)	Description: Ongoing supply chain disruptions across nations like the United States have led to limited availability of essential transplant medications. Impact: Price inflation and risk of treatment interruption will likely create opportunities for alternative therapies and market entry of generic/biosimilar formulations.

Competitor Insights

Key companies in kidney transplant medicine market report:

-       Merck & Co.

-       Roche

-       HLA Typing Solutions

-       Novartis

-       Astellas Pharma

-       Sanofi

-       Celgene Corporation

-       Bristol-Myers Squibb

-       AbbVie

-       Gilead Sciences

-       Teva Pharmaceutical Industries

-       Takeda Pharmaceutical Company

-       Pfizer

-       Amgen

-       Fresenius Medical Care

Key Developments

In March 2025, Zydus Lifesciences launched a breakthrough medication called ANVIMO for preventing cytomegalovirus infection in kidney transplant and haematopoietic stem cell transplant patients.

In February 2025, the U.S. FDA approved Nexus Pharmaceuticals’ Tacrolimus Injection 5 mg/mL. This new approval will offer a new ray of hope for patients requiring immunosuppressive therapy, such as those undergoing organ transplants.

In June 2024, Takeda Pharmaceutical Company Limited received approval for LIVTENCITY (maribavir) in Japan for post-transplant cytomegalovirus infection.

Market Segmentation

·          Product Type Insights (Revenue, USD Bn, 2020 - 2032)

o    Immunosuppressants

§  Calcineurin Inhibitors

§  Corticosteroids

§  mTOR Inhibitors

§  Biologic Agents

§  Antiproliferatives

o    Antibiotics

o    Antiviral Agents

o    Others

·          Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)

o    Oral

o    Intravenous

·          Indication Insights (Revenue, USD Bn, 2020 - 2032)

o    Kidney Transplant Rejection

o    Infection Management

·          Patient Age Insights (Revenue, USD Bn, 2020 - 2032)

o    Adult

o    Pediatric

·          Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)

o    Hospital Pharmacies

o    Retail Pharmacies

o    Online Pharmacies

·         Regional Insights (Revenue, USD Bn, 2020 - 2032)

o    North America

§  U.S.

§  Canada

o    Latin America

§  Brazil

§  Argentina

§  Mexico

§  Rest of Latin America

o    Europe

§  Germany

§  U.K.

§  Spain

§  France

§  Italy

§  Russia

§  Rest of Europe

o    Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

§  ASEAN

§  Rest of Asia Pacific

o    Middle East

§  GCC Countries

§  Israel

§  Rest of Middle East

o    Africa

§  South Africa

§  North Africa

§  Central Africa

Also Read: Artificial Kidney Market Size and Share Analysis (2025-2032)

Our Trusted Partners:
Worldwide Market Reports, Coherent MI, Stratagem Market Insights

Get Recent News:
https://www.coherentmarketinsights.com/news

About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights

Phone:

US: + 12524771362

UK: +442039578553

AUS: +61-2-4786-0457

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com

Website: https://www.coherentmarketinsights.com
For Latest Update Follow Us:
LinkedIn | Facebook | Twitter